Second-line therapy with fingolimod for relapsing-remitting multiple sclerosis in clinical practice: the effect of previous exposure to natalizumab.

Assunta Bianco,Agata Katia Patanella,Viviana Nociti,Alessandro Marti,Giovanni Frisullo,Domenico Plantone,Chiara De Fino,Anna Fetta,Anna Paola Batocchi,Paolo Maria Rossini,Massimiliano Mirabella

Second-line therapy with fingolimod for relapsing-remitting multiple sclerosis in clinical practice: the effect of previous exposure to natalizumab.

2015

Assunta Bianco
Agata Katia Patanella
Viviana Nociti
Alessandro Marti
Giovanni Frisullo
Domenico Plantone
Chiara De Fino
Anna Fetta
Anna Paola Batocchi
Paolo Maria Rossini
Massimiliano Mirabella

Background: To evaluate efficacy and safety of fingolimod for relapsing-remitting multiple sclerosis, particularly in patients previously exposed to natalizumab.

Keywords:

Multiple sclerosis
Clinical Practice
Anesthesia
Diabetes mellitus
Second-line therapy
Side effect
Fingolimod
Natalizumab
Medicine
Physical therapy
Internal medicine
Adverse effect
relapsing remitting
Oncology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations